Alphabet Replaces Verizon in Dow Jones Industrial Average 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Nomura Stock Upgraded to Buy by BofA as Stronger ROE and Earnings Growth Boost Outlook 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
GAITHERSBURG, Md., Feb. 20, 2017 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its fourth quarter and full year 2016 financial and operating results following the close of U.S. financial markets on Monday, February 27, 2017.
Conference call details are as follows:
| Date: | Monday, February 27, 2017 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” | |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, February 27, 2017, until midnight March 3, 2017 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 61206704 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until April 30, 2017 | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Investor Relations Novavax, Inc. Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Westwicke Partners John Woolford [email protected] 443-213-0506 Media Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] 212-845-4271
